상세 보기
CLINICAL IMPACT BY 24 MONTHS ACCORDING TO BCR/ABL1 TRANSCRIPT LEVEL AT 3 AND 6 MONTHS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH RADOTINIB 300MG BID OR IMATINIB
- Do, Y. R.;
- Kwak, J. -Y.;
- Kim, H.;
- Kim, J. -A.;
- Kim, H. J.;
- ... Park, J.;
- 외 18명
Citations
WEB OF SCIENCE
0- 제목
- CLINICAL IMPACT BY 24 MONTHS ACCORDING TO BCR/ABL1 TRANSCRIPT LEVEL AT 3 AND 6 MONTHS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH RADOTINIB 300MG BID OR IMATINIB
- 저자
- Do, Y. R.; Kwak, J. -Y.; Kim, H.; Kim, J. -A.; Kim, H. J.; Park, J. S.; Chung, J. S.; Shin, H. -J.; Kim, S. -H.; Kim, D. -Y.; Bunworasate, U.; Choi, C. W.; Comia, N. S.; Zang, D. Y.; Oh, S. J.; Jootar, S.; Reksodiputro, A. H.; Lee, W. S.; Mun, Y. -C.; Kong, J. H.; Caguioa, P. B.; Park, J.; Jung, C. W.; Kim, D. -W.
- 발행일
- 2017-06
- 유형
- Meeting Abstract
- 저널명
- Haematologica
- 권
- 102
- 페이지
- 441 ~ 441